Sun Pharma

Updated data from the CK-301-101 trial showed durable responses and manageable safety profile in patients with locally advanced cutaneous squamous cell carcinoma

Indian pharmaceutical companies are investing in specialty drugs, biosimilars and local manufacturing in the US despite a near 10 per cent fall in exports in FY26

In the March quarter, Sun Pharma reported net profit at ₹2,714 crore, as compared to ₹2,150 crore a year ago, up 26.2 per cent year-on-year (Y-o-Y)

Innovative medicines business crosses $1 billion milestone as company expands specialty pipeline and bets on Organon acquisition

India's largest drugmaker reported stronger-than-expected quarterly profit as growth in specialty medicines offset weakness in US sales

Q4FY26 company results: Firms including Hindalco Industries, Fortis Healthcare, Torrent Pharmaceuticals, Info Edge (India), and TTK Prestige are also to release their January-March earnings today

The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk

Sun Pharma's acquisition of Organon as a transformational deal, doubling revenue to USD 12 billion with 30 per cent EBITDA margin, analysts.

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

The Indian drugmaker is considering seeking consent from Organon bondholders to swap their holdings into Sun Pharma debt

India’s largest drugmaker by market capitalisation, Sun Pharmaceutical Industries Ltd, is set to acquire US-based Organon & Co for an enterprise value of $11.75 billion in one of the largest overseas

Nandish Shah of HDFC Securities has shared Bull Spread' on strategy on Midcap Nifty and Sun Pharma

According to bankers, the Indian pharma major plans to raise around $10 billion from various sources, while the remaining will be funded through internal accruals

Supported by the Sun Pharma's proven record of strong cash flows, analysts remain confident in gradual deleveraging over time.

Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term efficiencies through a stronger commercial front-end

From India's FTA strategy and Sun Pharma's global ambitions to LPG shortages, West Asia risks and Asean ties, here are the key insights from today's Opinion page

Organon's portfolio includes over 70 products across women's health and biosimilars

Sun Pharma's $11.75 billion Organon deal could boost its global scale and biosimilars reach, but investors are closely watching debt levels, execution risks and long-term returns

Combined entity to have revenue of $12.4 billion; enters biosimilars big league

Sun Pharma's Organon deal lifts stock, but growth concerns and high debt at the acquired firm may cap upside despite synergy potential